COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
1 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 14, 2021 |
Jun. 04, 2020 |
May 08, 2020 |
Dec. 10, 2015 |
Oct. 30, 2020 |
Feb. 20, 2020 |
May 30, 2019 |
Mar. 28, 2019 |
Sep. 30, 2021 |
Sep. 30, 2019 |
Dec. 31, 2019 |
Dec. 31, 2020 |
|
| Consideration amount | $ 41,600 | $ 314,600 | $ 894,600 | |||||||||
| Research and development expenses | $ 1,125,098 | |||||||||||
| Common stock shares issued, descripiton | the other one was with the J and R Galligan Revocable Trust, managed by Mr. Joseph Galligan, a holder of between 5% and 10% of the Company's shares of common stock | |||||||||||
| Compensation for services, descriptions | the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company's majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company's IND application; (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) one consultant shall receive common stock equivalent to $6,667 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month. | |||||||||||
| Remuneration amount | $ 5,500 | |||||||||||
| Common stock issued upon convertible debt | 2,227,575 | |||||||||||
| Lucido [Member] | ||||||||||||
| Common stock, Shares issued | 200,000 | |||||||||||
| Alpine Creek [Member] | ||||||||||||
| Total consideration amount | $ 1,531,926 | |||||||||||
| Payables to Alpine Creek | $ 1,215,000 | |||||||||||
| Payable commitment description | Alpine Creek fifty percent (50%) for each Treatment following the Effective Date until the Company has paid Alpine Creek an aggregate of $1,620,000, with the exception of treatments conducted in certain territories. | On any other proprietary implant distribution, that excludes the "treatment", for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company's gross profit for implant distribution not to exceed $100 per sale. | ||||||||||
| Payable per treatment sold | $ 100 | |||||||||||
| Royalty due | $ 91 | $ 91 | ||||||||||
| Profit holding percentage | 50.00% | |||||||||||
| Sinclair [Member] | ||||||||||||
| Remaining commitment | 30,840 | |||||||||||
| Charles River Laboratories, Inc. [Member] | ||||||||||||
| Consideration amount | $ 3,024,476 | |||||||||||
| Remaining commitment | $ 122,178 | |||||||||||
| BICX Holding Company LLC [Member] | ||||||||||||
| Common stock issued upon convertible debt | 2,227,575 | 2,227,575 | ||||||||||
| Convertible Promissory Note | $ 4,160,000 | |||||||||||
| Conversion agreement description | Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company's financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment | |||||||||||
| Issuance price | $ 2.00 | |||||||||||
| Gross proceeds | $ 10,000,000 | |||||||||||
| January 1, 2021 [Member] | Mr. Joseph Galligan [Member] | ||||||||||||
| Subscription and royalty agreement description | Mr. Joseph Galligan, a holder of between 5% and 10% of the Company’s shares of common stock, Director and Senior Advisor acquired from Alpine Creek the rights to the royalty agreement by and between the Company and Alpine Creek. | |||||||||||
| Advisory Board Agreement [Member] | ||||||||||||
| Common stock shares descriptions | In compensation for services, each advisory board member shall receive common stock equivalent to $5,000 on the last day of such quarter when meetings are held. | |||||||||||
| Galligan Subscription and Royalty Agreement [Member] | ||||||||||||
| Common stock, Shares issued | 200,000 | |||||||||||
| Agreement descriptions | The terms and conditions of the Galligan Subscription and Royalty Agreement (including the amount of shares of Common Stock purchased, the Purchase Price, and the terms of the Royalty) are substantially the same as the Lucido Subscription and Royalty Agreement except that the Company will have complete discretion as to the exact amount of $3,000,000 of the Galligan Subscription and Royalty Agreement to be allocated to the development and expansion of the Business. | |||||||||||
| Lucido Subscription and Royalty Agreement [Member] | ||||||||||||
| Subscription and royalty agreement description | Pursuant to the Lucido Subscription and Royalty Agreement: (i) Mr. Lucido purchased shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the "Purchase Price"), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay Lucido (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the "Initial Sales Date") and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the "Royalty"). | |||||||||||
| Development and expansion expenses amount | $ 3,000,000 | |||||||||||
| Description for the use of proceeds under agreement | The Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Company's weight loss program (the "Business") including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development. The Company received consent of Mr. Lucido to use more than 35% of the aggregate Purchase Price for general working capital and administration, and for further product development. | |||||||||||
| Restricted Stock Agreement [Member] | ||||||||||||
| Common stock shares descriptions | the Company entered into a twelve (12) month restricted stock agreement with one employee. Pursuant to which the employee shall be issued, upon the last day of each month, the number of shares of the Company's common stock equivalent to $2,500 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. | |||||||||||